Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-23

    Virtual Booth

    An Enquiry

    Menu

    Fasedienol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,120Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vistagen to Release Fasedienol PALISADE-3 Data Q4
    Vistagen to Release Fasedienol PALISADE-3 Data Q4

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602738861/en/Vistagen-on-Track-to-Deliver-Topline-Data-From-Fasedienol-PALISADE-3-Phase-3-Trial-for-Acute-Treatment-of-Social-Anxiety-Disorder-in-the-Fourth-Quarter-of-This-Year

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol
    Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923438804/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder
    Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401402849/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
    Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray

    10 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/affamed-therapeutics-announces-partner-vistagen-reports-positive-top-line-results-from-phase-3-palisade-2-trial-of-fasedienol-ph94b-nasal-spray-in-social-anxiety-disorder-301897671.html

    PR NEWSWIRE
    10 Aug 2023
    Share Share
    Vistagen stock soars 1,272% on social anxiety spray data
    Vistagen stock soars 1,272% on social anxiety spray data

    08 Aug 2023

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vistagens-stock-skyrockets-1272-after-social-anxiety-nasal-spray-hits-phase-3-trial-goals

    Gabrielle Masson FIERCE BIOTECH
    08 Aug 2023
    Share Share
    Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol
    Vistagen Announces Positive Results from Phase 3 Trial of Fasedienol

    07 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230807764660/en

    BUSINESSWIRE
    07 Aug 2023
    Share Share